EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BET inhibition curbs macrophage inflammation, lipid accumulation, and atherogenesis by disrupting the YAP/TAZ-BRD4 axis

Praveen Krishna Veerasubramanian, Vijaykumar S Meli, Hamza Atcha, Wenqi Wang iD, Timothy L Downing, Wendy F Liu iD

Journal of Leukocyte Biology · 2026

DOI: 10.1093/jleuko/qiag017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2026. Verfasst von Praveen Krishna Veerasubramanian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of California Irvine, Irvine, CA 92697, United States. Hauptthemen laut MEDLINE: Transcription Factors, Atherosclerosis, Macrophages, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edwards Lifesciences, University of California, Irvine, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophage dysfunction is hallmark of atherosclerotic disease, characterized by inflammation and uptake of oxidized low-density lipoproteins. We investigate the role of the epigenetic reader bromodomain-containing protein 4 (BRD4) in orchestrating macrophage responses through interactions with the mechanosensitive transcriptional coactivators YAP/TAZ. Suppression of BRD4 via bromodomain and extra-terminal motif (BET) protein inhibitors (BETi) unveils a remarkable capacity to mitigate YAP/TAZ-driven inflammation. Knockdown of YAP, TAZ, or BRD4 in macrophages shows a significant convergence of inflammatory genes under the regulatory purview of these transcriptional regulators. In addition, persistent activation of YAP and TAZ initiates a partial inflammatory phenotype in macrophages, which is effectively ameliorated with BETi. Notably, CD36 and low-density lipoprotein receptor-1 (LOX1), pivotal receptors involved in uptake of oxidized low-density lipoprotein, emerge as direct YAP/TAZ targets. We employed a BD2-specific BETi, ABBV-744, in an AAV-PCSK9-induced atherosclerosis model to test the therapeutic potential of BET inhibition. Although reduction in cholesterol levels is modest, BETi substantially curtails plaque formation, diminishing macrophage infiltration, and suppressing the upregulation of YAP/TAZ and oxidized low-density lipoprotein uptake receptors associated with atherogenesis. Intriguingly, even in conditions marked by heightened YAP/TAZ expression induced by myeloid cell-targeted YAP/TAZ overexpression, BETi effectively dampens inflammation, mitigates foam cell formation, and disease progression. Our work underscores the considerable promise of targeting the YAP/TAZ-BRD4 axis as a therapeutic strategy for averting atherosclerosis, thereby disrupting the relentless cycle of inflammation, mechanosensory responses, and oxLDL uptake characteristic of atherosclerosis progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsAtherosclerosisMacrophagesInflammationCell Cycle ProteinsAdaptor Proteins, Signal TransducingLipid MetabolismNuclear ProteinsHumansAnimalsBromodomain Containing ProteinsYAP-Signaling ProteinsLipoproteins, LDLMice

Stichwörter der Autor:innen

BRD4YAPinflammationlipidmacrophage

Substanzen

Transcription FactorsCell Cycle ProteinsBromodomain Containing ProteinsAdaptor Proteins, Signal TransducingYAP-Signaling ProteinsBRD4 protein, humanLipoproteins, LDLNuclear ProteinsYAP1 protein, humanoxidized low density lipoprotein

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of California Irvine, Irvine, CA 92697, United States.
  • UCI Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center (CIRC), University of California Irvine, Irvine, CA 92697, United States.
  • Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA 92697, United States.
  • NSF-Simons Center for Multiscale Cell Fate Research, University of California Irvine, Irvine, CA 92697, United States.
  • Department of Microbiology and Molecular Genetics, University of California Irvine, Irvine, CA 92697, United States.
  • Chemical and Biomolecular Engineering, University of California Irvine, Irvine, CA 92697, United States.

ORCID-Profile: Wenqi Wang, Wendy F Liu

Förderung

  • Edwards Lifesciences
  • University of California, Irvine
  • NIAMS NIH HHS
  • NIAID NIH HHS
  • NSF
  • National Institute of Allergy and Infectious Diseases
  • NCI NIH HHS
  • NIBIB NIH HHS

Zitieren

APA

Veerasubramanian, P. K., Meli, V. S., Atcha, H., Wang, W., Downing, T. L., & Liu, W. F. (2026). BET inhibition curbs macrophage inflammation, lipid accumulation, and atherogenesis by disrupting the YAP/TAZ-BRD4 axis. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiag017

Vancouver

Veerasubramanian PK, Meli VS, Atcha H, Wang W, Downing TL, Liu WF. BET inhibition curbs macrophage inflammation, lipid accumulation, and atherogenesis by disrupting the YAP/TAZ-BRD4 axis. Journal of Leukocyte Biology. 2026. doi:10.1093/jleuko/qiag017

BibTeX
@article{Veerasubramanian2026,
  author = {Veerasubramanian, Praveen Krishna and Meli, Vijaykumar S and Atcha, Hamza and Wang, Wenqi and Downing, Timothy L and Liu, Wendy F},
  title = {BET inhibition curbs macrophage inflammation, lipid accumulation, and atherogenesis by disrupting the YAP/TAZ-BRD4 axis},
  journal = {Journal of Leukocyte Biology},
  year = {2026},
  doi = {10.1093/jleuko/qiag017}
}
Kostenlos starten →